The technique of measuring thrombin generation with fluorogenic substrates: 1. Necessity of adequate calibration

Summary

In fluorogenic thrombin generation (TG) measurement the concentrations of thrombin are obtained from the course of fluorescence intensity. Because of fluorescence quenching, in one series of normal plasmas (n=60), the rate of fluorescence increase at fixed thrombin activity was 70 ± 13% of that in buffer, in another (n= 139) 75 ± 8%. Using a calibration factor (CF) measured in buffer therefore underestimates thrombin concentrations in plasma and introduces a source of error. A fixed CF also neglects the 25 – 35% increase of CF during the experiment and thus distorts the form of the TG curve so that the ETP cannot be determined. Continuous individual calibration (CIC), in which CF is determined continuously in a parallel sample, avoids such systematic errors but adds random error because the thrombin course is calculated from two different measurements. We determined the intra-individual coefficients of variation (CV) of the peak-height and ETP as obtained with CIC to those obtained with a fixed CF measured in buffer. With the fixed CF, the CVs varied between 18% and 49%; with CIC they lowered to 4–7% (n=5x12), i.e. in a range allowing clinical application. It is shown that CIC can be discarded for the measurement of peak thrombin values and replaced by comparison to a reference plasma only if quenching is not a systematic confounder. This was shown to be the case in the set of 139 normal plasmas but not in the set used for determining the intraindividual CVs, a difference that may depend upon preanalytical conditions.

Keywords

Thrombin generation - fluorogenic methods - calibration

• References

• 1 Hemker HC, Al Dieri R, Béguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004; 11: 170-175.
• 2 Hemker HC, Béguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: 747-751.
• 3 Turecek PL, Varadi K, Keil B. et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol HaemostThromb 2003; 33: 16-22.
• 4 Varadi K, Négrier C, Berntorp E. et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 01: 2374-2380.
• 5 Dargaud Y, Lienhart A, Meunier S. et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005; 11: 552-558.
• 6 Beltran-Miranda CP, Khan A, Jaloma-Cruz AR. et al. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-334.
• 7 Al Dieri R, Peyvandi F, Santagostino E. et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: 576-582.
• 8 Wielders S, Mukherjee M, Michiels J. et al. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability. ThrombHaemost 1997; 77: 629-636.
• 9 Reverter JC, Béguin S, Kessels H. et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 anti-body. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest 1996; 98: 863-874.
• 10 Curvers J, Thomassen MC, Rimmer J. et al. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-basedAPC resistance test. Thromb Haemost 2002; 88: 5-11.
• 11 Hezard N, Bouaziz-Borgi L, Remy MG. et al. Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency. Clin Chem 2006; 52: 665-670.
• 12 Rotteveel RC, Roozendaal KJ, Eijsman L. et al. The influence of oral contraceptives on the time-integral of thrombin generation (thrombin potential). Thromb Haemost 1993; 70: 959-962.
• 13 Rosing J, Middeldorp S, Curvers J. et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-2040.
• 14 Haidl H, Cimenti C, Leschnik B. et al. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). Thromb Haemost 2006; 95: 772-775.
• 15 Hemker HC, Al Dieri R. Age-dependency of throm-bin generation. Thromb Haemost 2006; 95: 756-757.
• 16 Dargaud Y, Trzeciak C, Bordet JC. et al. Use of Calibrated automated thrombinography ± thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost 2006; 96: 562-567.
• 17 Hron G, Kollars M, Binder BR. et al. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. J Am Med Assoc 2006; 296: 397-402.
• 18 Hemker HC, Giesen PL, Ramjee M. et al. The thrombogram: monitorring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-591.
• 19 Hemker HC, Giesen P, Al Dieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Patho-physiol Haemost Thromb 2002; 32: 249-253.
• 20 Regnault V, Hemker HC, Wahl D, Lecompte T. Phenotyping the haemostatic system by thrombography--potential for the estimation of thrombotic risk. Thromb Res 2004; 114: 539-545.
• 21 Spronk H, Dielis A, de Smedt E. et al. Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 2008; 99: 362-364.
• 22 Hemker HC, De Smedt E. Caution in the interpretation of conitinous thrombin generation assays: a rebuttal. J Thromb Haemost 2007; 05: 1085-1087.
• 23 Hron G, Eichinger S, Weltermann A. et al. Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time. J Thromb Haemost 2006; 04: 752-756.